ARTICLE | Clinical News
Arzerra ofatumumab regulatory update
September 28, 2015 7:00 AM UTC
FDA has accepted and granted Priority Review to an sBLA from Novartis for Arzerra ofatumumab for maintenance treatment of relapsed chronic lymphocytic leukemia (CLL). The PDUFA date is Jan. 21, 2016. ...